Resistance to apoptosis is one of the hallmarks of human cancers and contributes to the insensitivity of many cancers to commonly used treatment approaches. Inhibitor of apoptosis (IAP) proteins, a family of anti-apoptotic proteins, have an important role in evasion of apoptosis, as they can both block apoptosis-signaling pathways and promote survival. High expression of IAP proteins is observed in multiple cancers, including hematological malignancies, and has been associated with unfavorable prognosis and poor patients' outcome. Therefore, IAP proteins are currently considered as promising molecular targets for therapy. Indeed, drug-discovery approaches over the last decade aiming at neutralizing IAP proteins have resulted in the generation of small-molecule inhibitors or antisense oligonucleotides that demonstrated in vitro and in vivo antitumor activities in preclinical studies. As some of these strategies have already entered the stage of clinical evaluation, for example, in leukemia, an update on this promising molecular-targeted strategy to interfere with apoptotic pathways is of broad interest.
INTRODUCTION
Apoptosis is a form of programmed cell death, which is broadly involved in the regulation of various physiological and pathophysiological processes. 1 The balance between cell death by apoptosis on one side and proliferation on the other side is one of the critical factors to maintain tissue homeostasis. 1 Especially in the hematopoietic system with its physiologically high turnover of cells and its intrinsic ability to proliferate, apoptotic cell death serves as a barrier to oppose uncontrolled proliferation. 2 Thus, subtle changes in this delicate balance between cell death and proliferation, for example, due to a reduced rate of cell death, may have detrimental effects and can contribute to leukemogenesis. In addition, the majority of anticancer therapies that are currently used in clinical protocols exert their therapeutic effects via the activation of this intrinsic cell death program in cancer cells. 3 Accordingly, evasion of apoptosis may contribute to treatment resistance of cancers. 4 Defective apoptosis may be caused by the dominance of programs that block apoptosis. 4 For example, inhibitor of apoptosis (IAP) proteins are a family of endogenous inhibitors that interfere with apoptosis-signaling pathways at several key nodes. 5 Expression and/or function of IAP proteins are misregulated in various cancers, including hematological malignancies, for example, due to genetic lesions or alterations in signal transduction. This implies that IAP proteins represent promising molecular targets for therapy and drug discovery. In recent years, there have been major advances in the elucidation of the biology of IAP proteins, as well as in the development of therapeutic strategies to target IAP proteins. This review focuses on the role of IAP proteins and their therapeutic targeting in hematological malignancies.
APOPTOTIC SIGNAL TRANSDUCTION
Two principal apoptosis-signaling pathways have been identified, that is, the death receptor (extrinsic) pathway and the mitochondrial (intrinsic) pathway ( Figure 1) . 3 In the death receptor pathway, binding of the death receptor ligands of the tumor necrosis factor (TNF) receptor superfamily to their related receptors such as TNF receptor, CD95 or TNF-related apoptosisinducing ligand (TRAIL) receptors initiates oligomerization of receptors, which serves as a signal to assemble the adapter molecule Fas-associated death domain (FADD) and caspase-8 at activated death receptors to form the death-inducing signaling complex. 6 This leads to activation of caspase-8, which either directly cleaves effector caspase-3 or, alternatively, engages the mitochondrial pathway of apoptosis by cleaving Bid. Following its cleavage, truncated Bid relocates to mitochondria and promotes the mitochondrial outer membrane permeabilization. 3 This in turn leads to the release of mitochondrial intermembrane proteins into the cytosol, such as cytochrome c or second mitochondria-derived activator of caspase (Smac)/direct IAP-binding protein with low PI (DIABLO). 7 In the cytosol, cytochrome c promotes the assembly of the apoptosome complex that drives caspase-9, and subsequently, caspase-3 activation, whereas Smac/DIABLO facilitates caspase-3, -7 and -9 activation by binding and neutralizing the IAP proteins. 7 Signal transduction to apoptotic cell death is tightly controlled by a range of pro-and anti-apoptotic factors, for example, by IAP proteins. 5 
IAPS: STRUCTURE AND FUNCTION
IAP proteins constitute a family of proteins that are evolutionary highly conserved. 5 In humans, they comprise eight analogs (Table 1) . Cellular IAP1 (cIAP1), cIAP2, X-linked IAP (XIAP), melanoma-IAP (ML-IAP) and survivin are the family members that have been most extensively studied. 5 As there are excellent recent reviews on survivin, 8, 9 this review will focus on XIAP, cIAP proteins and ML-IAP.
Three key structural elements are characteristic for the IAP family of proteins. 5 First, the baculoviral IAP repeat (BIR) domain of 70 --80 amino acids is present in all members of the family, and at least one BIR motif is required for the classification as an IAP protein. Second, several IAP proteins harbor the Really Interesting New Gene (RING) domain, an E3 ubiquitin ligase that mediates ubiquitination and proteasomal degradation of various substrates; among them, caspases, Smac and IAP proteins themselves. 10 Third, the caspase activating and recruitment domain (CARD) represents a protein --protein interaction domain that is necessary for oligomerization with proteins that contain a CARD domain, for example, via auto-or heterodimerization.
XIAP, for example, is composed of three BIR domains and a RING motif at its C-terminus, and has been suggested to exert the strongest anti-apoptotic functions compared with other IAP proteins.
11 XIAP-imposed inhibition of caspase-3/-7 is mediated via the linker region preceding the BIR2 domain and the BIR2 domain ( Figure 1) . 12 --14 The BIR3 domain of XIAP inhibits active caspase-9 via two interaction points. First, a surface groove of BIR3 binds to the IAP-binding motif of the small subunit of active caspase-9 and, second, a separate part of XIAP --BIR3 binds to the stretch of caspase-9 that is required for caspase-9 homodimerization. 15, 16 Also, XIAP inhibits apoptosis via its E3-ligase activity by stimulating the proteasomal degradation of pro-apoptotic proteins, for example, caspases and Smac. 10 In addition, XIAP can contribute to nuclear factor (NF)-kB activation via several mechanisms, for example, via its ability to associate with TAK1 kinase and TAB1. 17 --21 cIAP1 and cIAP2 are considered to inhibit caspase activation by targeting caspases for proteasomal degradation via their RING domain rather than by directly inhibiting their catalytic activities. 22 Similarly, ML-IAP can regulate the protein stability of various cell death regulators, including caspases via its ubiquitin E3-ligase activity. 10 As E3 ligases, cIAP1 and cIAP2 can also promote canonical NF-kB activation via non-degradative K63 polyubiquitination of RIP1 ( Figure 1) . 23 --25 In addition, c-IAP1 and c-IAP2 can interfere with non-canonical NF-kB activation by mediating the constitutive proteasomal degradation of NF-kB-inducing kinase (NIK) via their E3-ligase activity ( Figure 1) . 26, 27 Further, cIAP1 has been described to stimulate proliferation by causing ubiquitination and degradation of Mad, a negative regulator of c-Myc. 28 ML-IAP comprises a single N-terminal BIR domain and a RING domain at its C-terminus 29, 30 and exists as two splice variants, that is, ML-IAPa with additional 18 amino acids at the linker region between the BIR and RING domains, and ML-IAPb. 31 ML-IAP interferes with apoptosis by inhibiting caspases and by sequestering Smac. 30, 32, 33 Interestingly, proteolytic cleavage of ML-IAP by caspases has been reported to turn the protein from an IAP into an apoptosis inducer. 34 Also, the anti-or pro-apoptotic function of ML-IAP may be regulated by its subcellular localization, as the pro-apoptotic function of truncated ML-IAP has been linked to its perinuclear localization. 35 Survivin represents the smallest member of the IAP protein family and harbors one BIR domain. 8, 9 The ability of survivin to inhibit apoptosis has been attributed to its interaction with Smac, to its binding to XIAP, thereby stabilizing the XIAP protein, and to its inhibitory action on mitochondrial apoptosis. 8, 9 IAP PROTEINS IN HEMATOLOGICAL MALIGNANCIES IAP proteins are expressed at elevated levels in various human cancers including hematological malignancies, for example, due to genetic alterations and/or abnormal activity of transcription factors that control the IAP protein expression. Abnormal expression of IAP proteins or endogenous IAP antagonists has been correlated with the patients' outcome or other clinical parameters in a number of studies as discussed in the following paragraphs (Table 2) .
XIAP, cIAP1 and cIAP2 in hematological malignancies Genetic evidence indicates that c-IAP1 and c-IAP2 are potential proto-oncogenes that are affected by chromosomal aberrations in cancers. Amplification of chromosomal DNA or chromosomal translocations are possible mechanisms that can lead to oncogenic activation in cancers. For example, the 11q21 --q23 amplification, which harbors the locus for both c-IAP1 and c-IAP2, has been identified in a variety of solid tumors and can contribute to elevated expression of c-IAP1 and c-IAP2, for example, in esophageal and pancreatic carcinoma. 36, 37 However, it remains to be determined whether or not overexpression of c-IAP1 and c-IAP2 in hematological malignancies is caused by gene amplification. Besides chromosomal amplifications, translocations between chromosomes constitute another mechanism that can cause abnormal gene expression. Chromosomal translocations are frequent events in leukemia and lymphoma, and have been implicated in the pathogenesis of abnormal expression of IAP proteins. The best-known example is the t(11;18)(q21;q21) translocation that yields a fusion product composed of the BIR domains of c-IAP2 and mucosa-associated lymphoid tissue (MALT)1. 38 --40 The t(11;18)(q21;q21) translocation is the most frequent chromosomal aberration in MALT lymphoma. 41 MALT1 is a paracaspase that harbors several functional domains, including a death domain, two immunoglobulin-like domains, a caspase-like domain and a globular domain. Although the caspase-like region is homologous to caspases, it lacks any protease activity. 42 Instead, MALT1 is an important mediator of NF-kB activation following, for 
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MALT lymphoma c-IAP2 t(11, 18)(q21;q21) translocation creates c-IAP2:MALT1 fusion protein in MALT lymphoma Dierlamm et al., 38 Akagi et al., 39 Morgan et al.
Multiple myeloma c-IAP1 Homozygous deletions of c-IAP1 chromosomal locus Keats et al., 65 Annunziata et al.
66
Multiple myeloma c-IAP2 Homozygous deletions of c-IAP2 chromosomal locus Keats et al., 65 Annunziata et al.
Abbreviations: IAP, inhibitor of apoptosis; ALL, acute lymphoblastic leukemia; AML, acute myelogenous leukemia; AMLL, acute mixed lineage leukemia; ATL, adult T-cell leukemia; c-IAP, cellular inhibitor of apoptosis; CLL, chronic lymphocytic leukemia; DLBCL, diffuse large B-cell lymphoma; HTLV-1, human T-cell leukemia virus type 1; MALT, mucosa-associated lymphatic tissue; ML-IAP, melanoma IAP; NHL, non-Hodgkin's lymphoma; Smac, second mitochondrial activator of caspases; XIAP, X-linked inhibitor of apoptosis.
example, T-cell receptor stimulation by ubiquitinating NF-kB essential modulator. 43 The c-IAP2 . MALT1 fusion protein that is created by the t(11;18)(q21;q21) translocation results in constitutive activation of the NF-kB pathway, independently of signaling regulators that normally control its activity. 44 As c-IAP2 belongs to the well-known anti-apoptotic NF-kB target genes, the c-IAP2 . MALT1 fusion protein-stimulated NF-kB activation engages a positive feed-forward amplification loop to further support the survival of cancer cells. This uncontrolled NF-kB activation is considered to be a critical event that contributes to malignant B-cell transformation and lymphoma progression in this disease.
Moreover, viral oncoproteins can contribute to abnormal expression of IAP proteins in hematological malignancies. In human T-cell leukemia virus type 1 (HTLV-1)-transformed adult T-cell leukemia, the viral oncoprotein Tax that is encoded by HTLV-1 aberrantly stimulates activation of the transcription factor NF-kB. 45 This in turn causes increased transcription of c-IAP2 as a prototype NF-kB target gene, leading to elevated protein expression of c-IAP2, a typical feature of adult T-cell leukemia. 45 Of note, this HTLV-1-stimulated, NF-kB-mediated abnormal expression of c-IAP2 contributes to the suppression of programmed cell death and supports the increased survival of HTLV-1-transformed lymphocytes. 45 This was demonstrated by RNA interference-mediated gene silencing of c-IAP2, which resulted in increased caspase activation and apoptosis along with reduced cell growth. 45 The prognostic significance of XIAP in acute myeloid leukemia (AML) has been controversially discussed. One study reported that AML patients with lower XIAP protein levels exhibited a significantly longer survival and also showed a tendency toward longer duration of remission compared with patients with higher XIAP protein levels. 46 In addition, XIAP expression was found to be significantly lower in AML patients with favorable cytogenetics compared with patients with intermediate or poor cytogenetics. 47 In contrast, no correlation between XIAP protein expression and cytogenetics, remission attainment or overall survival was observed in another large study of 172 primary AML samples. 48 It is interesting to note that high levels of XIAP protein in AML cell lines were reported to correlate with sensitivity rather than resistance to some chemotherapeutic drugs such as cytarabine. 46 Gene expression profiling analyzing 31 apoptosis-related transcripts in newly diagnosed AML patients identified a threegene expression signature, including c-IAP2, to accurately predict poor overall survival. 49 Surprisingly, high expression of two pro-apoptotic genes, that is, BAX-(l) and BMF, also correlated with unfavorable survival besides c-IAP2. 49 This indicates that the prognostic impact of this gene signature may be due to an altered balance of pro-and anti-apoptotic genes.
Furthermore, IAP proteins have recently been implicated in the regulation of apoptosis in core-binding factor (CBF) acute leukemias. 50 CBF leukemias are a subgroup of AML that are characterized by t(8;21) or inv(16)/t(16;16) translocations targeting the CBF, and are usually associated with a favorable prognosis. Gene expression profiling studies have previously identified two distinct CBF subgroups, independently of known molecular markers that exhibit significant differences in outcome. 51 Importantly, deregulated IAP expression and apoptotic signaling were among the signaling pathways that were found to differentiate these two clinically relevant CBF subgroups. 50 Whereas there is no consensus on the prognostic value of XIAP in adult AML, XIAP has been associated with adverse prognosis in pediatric leukemia by independent studies. Accordingly, high XIAP expression was identified as an unfavorable prognostic factor in childhood de novo AML. 52, 53 Elevated expression levels of XIAP mRNA and protein correlated with immature morphology, unfavorable cytogenetic risk groups, poor response to induction chemotherapy and worse 3-year relapse-free survival. 52, 53 Furthermore, high XIAP protein expression was associated with poor prednisone response in pediatric T-cell acute lymphocytic leukemia (ALL). 54 It is interesting to note that increased protein, but not mRNA, levels of XIAP were detected in childhood ALL cells compared with normal bone marrow mononuclear cells. 54 These findings point to a posttranslational mechanism that regulates XIAP expression. Indeed, XIAP contains an internal ribosomal entry site that can engage alternative translation initiation during cellular stress conditions to maintain XIAP protein expression. 55 Thus, XIAP expression may be aberrantly regulated post-transcriptionally in leukemia. However, additional studies are required to elucidate the exact molecular mechanisms that control the XIAP expression levels in childhood ALL.
In chronic lymphocytic leukemia (CLL), higher expression levels of several IAP proteins, including XIAP, c-IAP1 and c-IAP2, correlated with progressive disease. 56 Also, the expression of c-IAP1 and c-IAP2 was significantly higher in CLL cells than in non-malignant lymphocytes with concomitant downregulation of Smac expression. 56 Further, significantly higher protein levels of XIAP were found in CLL cells compared with healthy B cells. 57 In addition, CLL patients with progressive disease displayed lower levels of Smac compared with patients with stable disease. 56 These findings are consistent with an apoptosis-resistant profile of IAP proteins/IAP antagonists in CLL, especially in disease progression. Furthermore, c-IAP1 was identified by gene expression profiling as one of the genes that was upregulated in CLL cells, which were resistant to DNA damage-induced apoptosis, compared with sensitive samples. 58 By comparison, immunocytochemical analysis of c-IAP1, c-IAP2 and XIAP expression in CLL patients revealed no correlation between expression levels of IAP proteins and sensitivity to fludarabine-induced apoptosis or prognostic factors, 59 indicating that IAP protein expression was not generally linked to defective DNA-damage response. Moreover, gene expression profiling of the IAP genes in hematological malignancies unraveled a specific pattern of expression of c-IAP1, c-IAP2 and survivin in CLL, B-cell ALL and follicular lymphoma samples that discriminated these diseases from each other and from other entities. 60 In adult acute mixed-lineage leukemia, higher expression levels of XIAP and survivin were detected, compared with their expression levels in ALL, indicating that higher levels of several IAP proteins may contribute to the chemotherapy-resistant nature of this type of leukemia. 61 Immunohistochemical analysis of XIAP in diffuse large B-cell lymphoma showed that XIAP overexpression occurred in 55% of the diffuse large B-cell lymphomas and was significantly associated with adverse clinical outcome. 62 Moreover, elevated c-IAP2 mRNA levels were detected in mature neutrophils from a patient with chronic neutrophilic leukemia, but not in neutrophils from patients with chronic myelogenous leukemia. 63 Also, c-IAP2 expression was reported to be selectively upregulated by stimulation with granulocyte colony-stimulating factor, but not with granulocyte-macrophage colony-stimulating factor, 63 supporting the notion that c-IAP2-mediated suppression of apoptosis may promote survival and contribute to neutrophilia. In Hodgkin's lymphoma, high expression levels of XIAP were detected in Hodgkin and Reed --Sternberg cells. 64 It is interesting to note that there is also recent evidence that c-IAP1 and c-IAP2 can display tumor-suppressive properties under specific conditions. For example, it has been shown in multiple myeloma that various types of genetic aberrations can contribute to abnormal activation of canonical and non-canonical NF-kB signaling. 65, 66 For example, deletions of c-IAP1 and c-IAP2 were among the genetic alterations that lead to stimulation of the non-canonical NF-kB pathway. 65, 66 This discovery is consistent with the known function of c-IAP1 and c-IAP2 as E3 ligases that constitutively mediate the proteasomal degradation of NIK. 26, 27 Consequently, loss of function of c-IAP1 and c-IAP2 results in stabilization of NIK, which in turn phosphorylates and activates components of the NF-kB signaling cascade. 65, 66 ML-IAP in hematological malignancies There are diverging reports on the prognostic relevance of ML-IAP in acute leukemias, as it has been associated with both unfavorable and favorable prognosis. In adult acute leukemia, ML-IAP gene expression has been linked to poor prognosis, as higher mRNA levels of ML-IAP were detected in ALL and AML patients with displayed poor prognostic factors at diagnosis. 67 Also, ML-IAP mRNA levels inversely correlated with event-free, as well as overall survival in both forms of acute leukemia. 67 In contrast, ML-IAP turned out to be an independent factor predicting a superior prognosis in pediatric ALL. 68 In a study performed in 222 patients with childhood ALL, higher mRNA levels of ML-IAP were found in children with good prognostic factors, as well as in patients showing a favorable bone marrow response to induction chemotherapy at day 7. 68 Most importantly, multivariate analysis for relapse-free survival revealed that ML-IAP expression represents an independent factor for a good prognosis in childhood ALL. 68 How can these apparent discrepancies be reconciled? It is interesting to note that both anti-and proapoptotic properties have been attributed to ML-IAP. Inhibition of apoptosis by ML-IAP has been linked to its ability to sequester Smac, as it displays high binding affinities for Smac. 33 Furthermore, ML-IAP possesses a ubiquitin E3-ligase activity that can regulate the protein stability of various cell death regulators, including caspases. 10 By comparison, the pro-apoptotic effect of ML-IAP has been attributed to caspase-mediated cleavage of ML-IAP that generates a truncated form of ML-IAP, which has been documented to facilitate apoptosis. 34 The limited proteolysis of ML-IAP by caspase-mediated cleavage exposes an N-terminal domain that is critical for localization of truncated ML-IAP to the perinuclear region and its co-localization with the Golgi apparatus. 35 Although this perinuclear localization of truncated ML-IAP has been described to be essential for its pro-apoptotic function, it was found to be per se not sufficient. 35 Moreover, the RING domain of ML-IAP has been implicated to mediate its proapoptotic function. 35 Thus, ML-IAP may exert either anti-or proapoptotic activities, depending on the cellular context.
Smac/DIABLO in hematological malignancies
Multicolor flow cytometric analysis of Smac protein in newly diagnosed AML patients identified high expression levels of Smac as an independent favorable prognostic factor that correlated with higher complete remission rate and longer overall survival. 69 Also, there was a correlation of low protein levels of Smac and poor karyotype in the same patient cohort. 69 Analysis of Smac protein expression by immunohistochemistry in Hodgkin's lymphoma and non-Hodgkin's lymphoma tumor samples showed that Smac is expressed in a large proportion of Hodgkin's lymphoma (25/40 ¼ 63%) and non-Hodgkin's lymphoma (117/247 ¼ 47%). 70 It is interesting to note that Smac displayed a differential expression in distinct subtypes of non-Hodgkin's lymphoma. 70 Although Smac was expressed in most nonHodgkin's lymphoma subtypes in one-to two-thirds of tumors, lack of Smac expression was reported in a few subtypes, that is, small lymphocytic lymphoma, CLL and Burkitt lymphoma. 70 Also, Smac expression was rarely detected in extranodal marginal zone B-cell lymphoma. 70 By comparison, there was no preferential Smac expression in any subtypes of Hodgkin's lymphoma. 70 Further studies are necessary to address the prognostic relevance of Smac in lymphoma.
Survivin in hematological malignancies
Survivin represents the fourth most common transcriptome of the human genome in malignancies, whereas its expression levels are low in non-malignant cells, with the exception of some cell types such as hematopoietic stem cells. 8, 9 High expression of survivin was reported to bear an unfavorable prognosis in various hematological malignancies, for example, in anaplastic or diffuse large-cell lymphoma, AML, pediatric precursor B-cell ALL and adult T-cell leukemia. 8, 9 IAP PROTEINS AS THERAPEUTIC TARGETS IN HEMATOLOGICAL MALIGNANCIES Strategies to target IAP proteins As IAP proteins are expressed at elevated levels in several hematological malignancies and as they block cell death signaling pathways at key nodes, they are considered as promising molecular targets that can be exploited for the development of novel therapeutics. Therefore, several different approaches have been designed to antagonize IAP proteins, including smallmolecule inhibitors, peptides or antisense oligonucleotides.
In a first approach to neutralize the IAP proteins, peptides mimicking the endogenous IAP antagonist Smac were developed. These Smac peptides contain at least the first four N-terminal amino acids of Smac (i.e., Ala --Val --Pro --Ile), which have been shown to be essential for its binding to the BIR3 domain of XIAP and the linker region preceding the BIR2 domain of XIAP. 71 To ensure the efficient intracellular delivery of these peptides, they were linked to protein transduction domains; for example, using the TAT protein of HIV, the Drosophila antennapaedia penetratin sequence, or simply a polyarginine stretch. 72 --74 In an attempt to improve the potency and the pharmacological characteristics of IAP antagonists, a number of different peptidomimetics mimicking the N-terminal domain of Smac were subsequently designed. 75 --80 Although these compounds were initially composed as monovalent agents, 80, 81 further drugdiscovery efforts resulted in the generation of bivalent IAP antagonists made of two monovalent motifs with a central chemical linker. 82 --84 In general, bivalent IAP antagonists were described to exhibit higher binding affinities for IAP proteins and higher potency than monovalent IAP antagonists to induce cell death and to inhibit tumor growth. 82 --84 In addition to the small-molecule IAP antagonists, antisense oligonucleotides directed against XIAP have been developed. Single-stranded antisense oligonucleotides are composed of short patches of synthetic DNA containing usually 12 --30 oligonucleotides. 85 As these oligonucleotides are complementary to a corresponding mRNA strand, they interfere with the translational machinery in a target gene-specific manner. 85 AEG35156, a second-generation antisense oligonucleotide developed toward XIAP, was shown to dose-dependently downregulate the XIAP mRNA and protein levels in preclinical studies when it was administered in the low nanomolar range. 86 The suppression of XIAP levels in tumor tissues correlated with in vitro and in vivo antitumor effects of AEG35156. 86 Exploiting IAP antagonists for the treatment of hematological malignancies IAP antagonists have been extensively studied in recent years, both as single agents as well as in combination therapies in various human cancers including hematological malignancies (Table 3 ). In addition to directly triggering cell death when administered as monotherapy, IAP antagonists have been shown to prime cancer cells towards cell death induced by a variety of cytotoxic principles; among them, chemotherapeutic drugs, radiation, death receptor ligands and signal transduction inhibitors (Table 3) .
IAP antagonists in acute leukemias. Recent findings showing that deregulated IAP expression and apoptotic signaling differentiates two clinically distinct CBF subgroups with significant differences in clinical outcome 50, 51 provided the starting point for the evaluation of IAP antagonists in AML. Indeed, sensitivity of primary CBF AML samples to treatment with a Smac mimetic correlated with the gene expression profiles characteristic for the superior outcome CBF AML subgroup. 50 In addition, the response of CBF AML samples to the Smac mimetic correlated with significantly elevated levels of c-IAP1, c-IAP2, XIAP and NF-kB1. 50 These findings indicate that Smac mimetics may be particularly effective in a specific subgroup of CBF AML patients identified by gene expression profiling.
The small-molecule XIAP antagonist 1396-12 that is based on a polyphenylurea pharmacophore was reported to induce apoptosis at low micromolar concentrations in two-thirds of primary leukemia samples, although it was not lethal to normal hematopoietic cells in short-term cytotoxicity assays. 87 Sensitivity of primary AML specimens to XIAP inhibitor 1396-12 was associated with higher XIAP protein levels. 87 Furthermore, Smac mimetics LCL161 and LBW242 were shown to augment the effects of tyrosine kinase inhibitors in AML models. 88, 89 LBW242 enhanced cell death, in combination with either the fms-related tyrosine kinase 3 (FLT3) inhibitor PKC412 or the classical chemotherapeutic agents, such as doxorubicin and cytarabine, both in PKC412-sensitive as well as PKC412-resistant cell lines that express mutant FLT3. 88 In addition, LBW242 abrogated the resistance to PKC412 that was imposed by coculture with stromal cells. 88 Also in a xenograft mouse model in vivo, the combination of LBW242 and PKC412 was superior to either treatment alone to reduce tumor burden. 88 Similarly, the structural analog of LBW242, that is, LCL161 that has been optimized for potency and pharmacokinetics and that is a candidate for clinical trial investigation, was shown to increase nilotinib-or PKC412-induced apoptosis of AML in vitro and in vivo, both in the absence and the presence of a stromal-protected microenvironment. 89 Of note, LCL161 even demonstrated activity against drug-resistant cells expressing point mutations in the target proteins, including FLT3-internal tandem duplication harboring point mutations in the ATP-binding pocket of FLT3 and various imatinib-and nilotinib-resistant BCR-ABL point mutations. 89 In childhood ALL, IAP antagonists at subtoxic concentrations acted in concert with TRAIL to trigger apoptosis in a synergistic manner. 90 In contrast, a structurally related control compound did not synergize with TRAIL, underlining the specificity of the sensitizing effect provided by the IAP antagonists. 90 In addition, the IAP antagonist cooperated with TRAIL to suppress colony formation of ALL cells, 90 demonstrating an effect also on longterm clonogenic survival. Notably, IAP antagonists even bypassed Bcl-2-conferred resistance to TRAIL-induced apoptosis by switching type II leukemia cells, which depend on mitochondrial signaling for full activation of effector caspases, into type I cells that signal to TRAIL-induced caspase activation and apoptosis, independently of high Bcl-2 levels. 90 Furthermore, IAP antagonists as single agents triggered apoptosis in leukemic blasts from children with ALL ex vivo and also cooperated with TRAIL to induce apoptosis. Most importantly, the IAP antagonists were shown to significantly decrease the leukemic burden in a mouse model of childhood ALL in non-obese diabetic/severe combined immunodeficient mice in vivo. 90 Moreover, IAP antagonists were reported to act in concert with agonistic anti-CD95 antibodies or MegaFAS ligand, a hexameric form of CD95 ligand, to trigger apoptosis in pediatric ALL, including primary leukemic blasts from children with ALL. 91 Recently, it was also reported that the IAP antagonists cooperate with cytarabine to trigger apoptosis in ALL cells in a highly synergistic manner as calculated by combination index. 92 This synergism was similarly observed with a variety of chemotherapeutic drugs, including gemcitabine, cyclophosphamide, doxorubicin, etoposide, vincristine and taxol. 92 Mechanistically, RIP1 was identified as a critical regulator of the synergistic cooperation of the IAP antagonists and cytarabine.
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RIP1 was shown to be required for the assembly of a RIP1/FADD/ caspase-8 cell death complex in the cytosol that drives caspase-8 activation, mitochondrial outer membrane permeabilization and caspase-dependent apoptosis. 92 Indeed, silencing of RIP1 by RNA interference abrogated the formation of the RIP1/FADD/ caspase-8 complex and subsequent activation of caspase-8 and -3, mitochondrial perturbations and apoptosis, 92 confirming the critical role of RIP1 in this model of cell death. Similarly, inhibition of RIP1 kinase activity by the small-molecule inhibitor necrostatin-1 inhibited the IAP antagonist-and cytarabine-triggered interaction of RIP1, FADD and caspase-8, and apoptosis. 92 Importantly, the IAP antagonist also enhanced cytarabine-induced apoptosis in primary leukemic blasts, including samples from patients with high-risk disease, 92 underscoring the clinical relevance of this approach to enhance chemosensitivity of ALL. Furthermore, IAP inhibition using the Smac mimetic LBW242 significantly increased prednisone-induced apoptosis in a precursor B-cell ALL cell line. 54 In addition to TRAIL or CD95 receptor agonists, IAP antagonists have also been reported to act together with TNFa, another death receptor ligand, to induce cell death in leukemia cells. 93 --95 In this context, Smac mimetic-stimulated autodegradation of c-IAP1 and c-IAP2 was shown to cause deubiquitination of RIP1 and its release from the activated TNF receptor complex to form a caspase-8-activating platform containing RIP1, FADD and caspase-8 that triggers caspase-8 activation and apoptosis. 93 In contrast, Smac mimetic was recently shown to engage necroptotic cell death upon addition of TNFa in apoptosis-resistant ALL cells that were genetically deficient for FADD or caspase-8. 94 This type of cell death occurred in a strictly RIP1 kinase-dependent manner and lacked characteristic features of apoptotic cell death such as caspase activation or DNA fragmentation. 94 Similarly, Smac mimetic was shown to synergize with TNFa to trigger necroptosis in acute leukemia cells under conditions when caspases were inhibited. 96 Thus, IAP antagonists can potentiate TNFa-stimulated cell death by promoting either apoptosis or necroptosis in a context-dependent manner. In apoptosis-proficient cells that harbor FADD and caspase-8, IAP antagonists sensitize for TNFatriggered apoptosis. However, in apoptosis-resistant cells where caspase activation is inhibited, IAP antagonists cooperate with TNFa to engage necroptosis as a caspase-independent form of cell death. These findings open new perspectives to trigger alternative cell death programs in leukemia cells to overcome apoptosis resistance. These findings are in line with recent evidence of a close crosstalk between apoptotic and necroptotic cell death pathways from genetic mouse models. In these studies, key components of the extrinsic apoptosis pathway, including FADD and caspase-8, were shown to exert also non-apoptotic functions by preventing programmed necrosis. 97 --99 Of note, IAP antagonists failed to sensitize normal peripheral blood lymphocytes for TRAIL-, CD95-or Cytarabine-induced apoptosis. 90 --92 Also, IAP antagonists did not potentiate the toxicity of cytarabine on normal human hematopoietic progenitor cells or mesenchymal stroma cells. 92 These findings point to some tumor selectivity of IAP antagonists, which may open a therapeutic window. Further studies, however, are required to elucidate the molecular basis for this tumor selectivity. Together, these results indicate that IAP antagonists present a promising strategy for apoptosis-based therapy of childhood ALL, which warrants further investigation.
Evaluation of mono-and bivalent Smac mimetics in ALL, AML and CML cell lines showed that Smac mimetics acted in concert, in particular with TRAIL, to reduce viability of leukemia cells. 100 In addition, mono-and bivalent Smac mimetics significantly increased cytarabine-and etoposide-induced loss of viability in leukemia cells, whereas no cooperative interaction was reported for idarubicine or imatinib. 100 In contrast to their activity against leukemic cells, Smac mimetics exhibited modest effects on normal hematopoietic progenitors. 100 Furthermore, tetrapeptides and heptapeptides of Smac were shown to significantly increase apoptosis in ALL cells upon treatment with TRAIL or with the epothilone B-derivative BMS 247550. 101 IAP antagonists in chronic leukemias. Furthermore, IAP inhibitors and TRAIL were found to cooperatively induce apoptosis in CLL, which was accompanied by increased activation of caspase-3.
102
Inhibition of the combination treatment-induced apoptosis by the caspase inhibitor zVAD.fmk underscored that apoptosis occurred in a caspase-dependent manner. 102 Importantly, the cooperative induction of apoptosis by IAP inhibitor and TRAIL was even observed in several CLL subgroups with adverse prognostic parameters such as 17p deletion, p53 mutation, unmutated V(H) genes or chemoresistant disease. 102 Intriguingly, patients with unmutated V(H) genes were even significantly more responsive to IAP inhibitor-and TRAIL-triggered apoptosis, compared with cases with mutations in the V(H) genes, 102 although patients with unmutated V(H) genes bear a worse prognosis. 103 These findings suggest that B-cell receptor signaling may be involved in the regulation of apoptosis sensitivity in CLL cells. In an independent study, XIAP inhibitor was similarly shown to significantly increase TRAIL-induced apoptosis in the majority of primary CLL samples. 57 Also in this study, CLL patients with poor prognostic features, that is, ZAP-70 positivity, unmutated V(H) genes or 17p deletion, were found to be highly responsive to the combination of XIAP inhibitor and TRAIL. 57 Besides TRAIL, a XIAP antagonist was reported to significantly enhance CD95-induced apoptosis in CLL cells. 104 Together, these studies indicate that the combination of IAP inhibitors and TRAIL may present a new therapeutic approach especially in CLL patients with poor prognosis.
IAP antagonists in multiple myeloma. The Smac mimetic LBW242 was reported to induce apoptosis in multiple myeloma cell lines, as well as purified patient multiple myeloma cells that were resistant to conventional therapies or bortezomib. 105 In addition, LBW242-induced cell death was not affected by microenvironmental signals, for example, adherence to bone marrow stromal cells or the presence of interleukin-6 or insulin-like growth factor-1. 105 Also, overexpression of the anti-apoptotic protein Bcl-2 failed to confer protection against LBW242-induced cell death. 105 Importantly, LBW242 suppressed tumor growth and prolonged survival in human multiple myeloma xenograft mouse models without apparent toxicity. 105 Furthermore, LBW242 exerted additive or synergistic antitumor activity against multiple myeloma cells in combination with proteasome inhibitors such as bortezomib and NTI-0052, the death receptor ligand TRAIL, or the conventional cytotoxics such as melphalan. 105 These findings indicate that Smac mimetics alone or in combination therapies may be active against multiple myeloma, including cases of resistant disease.
IAP antagonists in Hodgkin's lymphoma. Neutralization of XIAP by RNA interference or Smac agonists in Hodgkin's lymphoma was reported to enhance the sensitivity of Hodgkin's lymphoma cells for cytotoxic T-cell attack, 106 indicating that XIAP targeting may enhance the efficacy of immunotherapies.
CLINICAL DEVELOPMENT OF STRATEGIES TARGETING THE IAP PROTEINS
From the many agents that have been developed over the last decade to target IAP proteins, XIAP antisense oligonucleotides and several small-molecule Smac-mimicking IAP antagonists have entered the clinical stage (Table 4) . Evaluation of AEG35156, a second-generation XIAP antisense oligonucleotide, in the first non-randomized phase I/II trial in AML, in combination with reinduction chemotherapy (i.e., high-dose cytarabine and idarubicin), demonstrated that AEG35156 dose-dependently caused knockdown of XIAP mRNA. 107, 108 Downregulation of XIAP expression correlated with the induction of apoptosis in one of four patients during the phase I trial and four of five patients during the phase II trial. 108 Also, the response rates correlated with the AEG35156 dose, that is, a higher overall response rate was observed among the patients receiving the highest AEG35156 dose. 107 Complete remissions following reinduction with AEG35156 and chemotherapy were reported in this nonrandomized trial in 10 of 11 patients (91%) that failed to achieve remission upon a single-induction chemotherapy.
107 AEG35156 was in general well tolerated in this study, with the exception of two cases with peripheral neuropathy. 107 In a subsequent randomized phase II trial, however, the addition of AEG35156 to reinduction chemotherapy with high-dose cytarabine and idarubicin did not improve the rates of remission compared with AML patients treated with the reinduction chemotherapy protocol alone. 109 Of note, pharmacodynamic studies to determine XIAP expression levels in response to XIAP antisense therapy were not included in the randomized phase II trial. As no data are available on the efficacy of target knockdown in this trial, it cannot be excluded that insufficient downregulation of XIAP may have contributed to the lack of clinical responses. However, the underlying reasons for the differences in the results of these clinical trials with AEG35156XIAP antisense are currently not known.
Furthermore, several IAP antagonists are presently undergoing evaluation in early clinical trials in advanced solid tumors and lymphoma (Table 4 ). All are pan-selective agents that broadly target different IAP proteins (i.e., XIAP, c-IAP1, c-IAP2 and ML-IAP) and comprise both monovalent and bivalent compounds (Table 4) . On theoretical grounds, monovalent agents offer the advantage of oral bioavailability, whereas bivalent compounds require intravenous administration. However, the question whether or not the latter exhibit a higher potency than monovalent antagonists in clinical trials, as suggested by preclinical studies, remains to be clarified. Also, the issue whether the higher potency of bivalent agents is accompanied by higher toxicity in the clinical setting remains to be addressed.
The monovalent antagonist LCL161 and the bivalent antagonists HGS1029 and TL32711 were all well tolerated in phase I trials. 110 --112 No dose-limiting toxicities were reported for LCL161 and TL32711, 110, 111 whereas dose-limiting toxicities including severe fatigue and elevated pancreatic enzymes were observed for HGS1029. 112 In addition, moderate side effects comprised lymphocytopenia and rash in two of these trials. 111, 112 Potent and sustained target inhibition in tumor and surrogate tissues was demonstrated by cIAP1 degradation, as well as by induction of cytokines such as MCP-1 and IL-8 in the circulation.
Also, circulating markers of cell death, that is, serum levels of cleaved cytokeratin-18 and activated caspase-3/-7, were upregulated upon administration of IAP antagonists, 110 --112 pointing to an apoptotic response. Preliminary evidence of antitumor activity was reported in some patients with solid cancers in the trials with TL32711 or HGS1029, 111, 112 whereas no objective response was observed following treatment with LCL161. 110 
FUTURE CHALLENGES
One of the key challenges for the future successful development of IAP antagonists in clinical trials will be the identification of markers that can be used for the selection of the types of cancers or the subgroups of patients that will likely respond to the IAP antagonists. Recent results in CBF acute leukemias showing that a specific gene expression signature is associated with sensitivity to IAP antagonists 50 provides a promising starting point for future studies to develop a biomarker in leukemia. Although preclinical studies suggest that the ability of cancer cells to mount an autocrine TNFa-signaling loop in response to IAP antagonists may predict their sensitivity to single-agent treatment, it remains to be determined whether this promise also holds true in primary tumor samples treated ex vivo with IAP antagonists and in clinical specimens derived from patients who are enrolled in the current early clinical trials with IAP antagonists. Also, little is yet known on potential biomarkers to monitor the treatment response to IAP antagonists in clinical trials. Circulating markers of cell death, that is, serum levels of cleaved cytokeratin-18 and activated caspase-3/-7, have been reported to be upregulated upon administration of IAP antagonists in current early clinical trials, in line with an apoptotic response. However, the question whether or not these parameters correlate with clinical responses remains to be clarified.
Another challenge resides in the preclinical and clinical development of rational combination therapies with IAP antagonists for the treatment of hematological malignancies. A series of preclinical studies indicate that the combination of IAP antagonists together with TRAIL receptor agonists may be particularly effective to synergistically trigger apoptosis in vitro and to suppress tumor growth in vivo in different cancers including leukemia. 90, 113, 114 Also, combinations of IAP antagonists and classical chemotherapeutics or targeted therapies such as FLT3 inhibitors showed encouraging results. 88, 89, 92 On the basis of the concept that neutralization of XIAP may release the break on caspase activation, such combinations of IAP antagonists as sensitizers, together with additional cytotoxic stimuli as cell death inducers, may prove to be particularly effective by exploiting additive or synergistic drug actions. Abbreviations: AML, acute myelogenous leukemia; IAP, inhibitor of protein; XIAP, X-linked inhibitor of apoptosis.
IAP proteins in hematological malignancies S Fulda CONCLUSIONS IAP proteins represent promising molecular targets for therapy in leukemia, lymphoma and multiple myeloma, given their aberrantly high expression in these malignancies, their potent antiapoptotic properties and their role in key survival signaling cascades. IAP targeting agents, including small-molecule inhibitors and antisense oligonuclelotides, proved to be effective to trigger apoptotic and non-apoptotic cell death in a series of preclinical studies in vitro and in vivo as monotherapy, and in particular, in combination protocols. Currently, several IAP antagonists are undergoing evaluation in early clinical trials. Thus, IAP antagonists represent promising novel antileukemic therapeutics that warrant further investigation.
